InsiderClue
← All stocks

CORCEPT THERAPEUTICS INC

CORT Net selling
CIK 0001088856 #827 in the set updated 17 Sep 2026
Bought (120 mo)
$17.22M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$294.89M
$47.06M on a plan · $179.57M straight out of an exercise
Sold at will
$68.26M
81 of 389 sales
Net
−$277.67M
−$51.04M against sales at will

By person

20 insiders · 482 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Maduck Sean
See Remarks
—
$57.91M (69) scheduled
−$57.91M
53,938
0.0499%
$6.03M
—
BELANOFF JOSEPH K
Chief Executive Officer
—
$50.86M (38) scheduled
−$50.86M
2,565,489
2.37%
$286.58M
+37.6%
ENRIGHT PATRICK G
Director
—
$45.33M (30)
−$45.33M
318,885
0.2950%
$35.62M
−96.0%
Lyon Joseph Douglas
See Remarks
—
$31.27M (49) scheduled
−$31.27M
5,683
0.0053%
$634.81K
—
Guyer William
Chief Development Officer
—
$28.44M (41) scheduled
−$28.44M
4,313
0.0040%
$481.78K
—
Mokari Atabak
Chief Financial Officer
—
$18.73M (22) scheduled
−$18.73M
16,304
0.0151%
$1.82M
—
MAHONEY DAVID L
Director
—
$17.40M (14) scheduled
−$17.40M
1,133,539
1.05%
$126.62M
+2.5%
BAKER G LEONARD JR
Director
$17.01M (32)
$1.77M (4) scheduled
+$15.24M
2,241,893
2.07%
$250.43M
+152.7%
Robb Gary Charles
Chief Business Officer
$54.59K (1)
$14.89M (34)
−$14.84M
108,666
0.1005%
$12.14M
+311.9%
Longitude Venture Partners L.P. entity
10% owner
—
$7.21M (16)
−$7.21M
10,956,002
10.14%
$1.22B
−25.5%
Vieira Roberto Wandenkolk
President, Oncology
—
$6.46M (7) scheduled
−$6.46M
4,242
0.0039%
$473.85K
+4.3%
WILSON JAMES N
Director
—
$5.29M (15) scheduled
−$5.29M
2,539,086
2.35%
$283.63M
−12.0%
Swisher Daniel N JR
Director
—
$3.90M (36) scheduled
−$3.90M
0
0.0000%
$0.00
—
Park Kimberly
Director
—
$3.27M (1) scheduled
−$3.27M
0
0.0000%
$0.00
—
FISHMAN ROBERT S
Chief Medical Officer
—
$1.52M (12) scheduled
−$1.52M
0
0.0000%
$0.00
—
Hunt Hazel
Chief Scientific Officer
—
$631.75K (1)
−$631.75K
255,437
0.2363%
$28.53M
+127,619%
GALA RENEE D
Director
$155.10K (2)
—
+$155.10K
10,000
0.0093%
$1.12M
—
Tammenoms Bakker Juliet
10% owner
—
—
—
133,539
0.1235%
$14.92M
—
BRADBURY DANIEL
Director
—
—
—
130,575
0.1208%
$14.59M
−26.6%
Cannon Gillian
Director
—
—
—
0
0.0000%
$0.00
—

Individual transactions

20
Insider
Date
Role
Action
Shares
Price
Amount
MAHONEY DAVID L
13 Mar 2026
Director
Exercised, kept
30,000
$5.86
$175.80K
WILSON JAMES N
24 Feb 2026
Director
Exercised, kept
100,000
$3.88
$388.00K
Hunt Hazel
9 Feb 2026
Chief Scientific Officer
Exercised, kept
150,000
$3.88
$582.00K
BAKER G LEONARD JR
27 Jan 2026
Director
Exercised, kept indirect
30,000
$15.15
$454.50K
BAKER G LEONARD JR
27 Jan 2026
Director
Exercised, kept indirect
25,000
$10.50
$262.50K
BAKER G LEONARD JR
27 Jan 2026
Director
Exercised, kept indirect
25,000
$14.08
$352.00K
BAKER G LEONARD JR
27 Jan 2026
Director
Exercised, kept indirect
30,000
$12.13
$363.90K
BAKER G LEONARD JR
27 Jan 2026
Director
Exercised, kept indirect
30,000
$5.86
$175.80K
BELANOFF JOSEPH K
24 Dec 2025
Chief Executive Officer
Exercised, kept
550,000
$3.88
$2.13M
Robb Gary Charles
24 Dec 2025
Chief Business Officer
Exercised, kept
145,000
$3.88
$562.60K
Cannon Gillian
4 Sep 2025
Director
Exercised, kept
11,000
$22.99
$252.89K
Maduck Sean
29 May 2025
See Remarks
Exercised, kept
10,000
$3.88
$38.80K
Hunt Hazel
11 Feb 2025
Chief Scientific Officer
Exercised, kept
150,000
$3.29
$493.50K
WILSON JAMES N
22 Jan 2025
Director
Exercised, kept
250,000
$3.29
$822.50K
Robb Gary Charles
3 Jan 2025
Chief Business Officer
Exercised, kept
3,037
$3.29
$9.99K
Hunt Hazel
1 Aug 2024
Chief Scientific Officer
Exercised, kept
60,000
$2.81
$168.60K
BELANOFF JOSEPH K
31 Jul 2024
Chief Executive Officer
Exercised, kept
450,000
$3.29
$1.48M
Robb Gary Charles
4 Jun 2024
Chief Business Officer
Exercised, kept
14,000
$3.29
$46.06K
MAHONEY DAVID L
10 Apr 2024
Director
Exercised, kept
30,000
$1.74
$52.20K
Maduck Sean
19 Mar 2024
See Remarks
Exercised, kept
10,000
$2.61
$26.10K
Showing 250 of 482 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 523
Amendments (4/A) skipped 6
Filings about a different issuer 0
Unreadable filings 0
Joint filings 4
Sales on a Rule 10b5-1 plan 50
Sales straight out of an exercise 258
Sales at will 81
Transactions with no price 0
Shares from compensation/vesting 25,932,916
Sales filed before the plan box existed 65
History held since 9 Nov 2016